8-K: Silexion Regains Nasdaq Compliance, Boosts Equity to $9.41M

Silexion Therapeutics Corp. announced it has regained compliance with Nasdaq's minimum shareholders' equity requirement, reporting approximately $9.41 million in equity following recent capital-raising activities.

Summary

• Issued 450,000 ordinary shares to Moringa Sponsor, LP upon conversion of $1.8 million of the outstanding Sponsor Convertible Note at a conversion price of $4.00 per share.
• The outstanding amount owed under the Sponsor Convertible Note is now $1.6 million.
• Affirmed shareholders' equity is approximately $9.41 million as of September 15, 2025, achieving compliance with Nasdaq Listing Rule 5550(b)(1) which requires at least $2.5 million.
• Shareholders' equity increased significantly from $0.1 million as of June 30, 2025, and a capital deficiency of $0.7 million as of July 31, 2025.
• The increase in equity resulted from several transactions: an August 2025 warrant exercise inducement ($1.5 million equity increase), a September 2025 public offering ($5.2 million equity increase), a September 2025 exercise of Series B ordinary warrants ($1.78 million equity increase), and the September 2025 partial conversion of the Sponsor Convertible Note ($1.83 million equity increase).

Sentiment

Score: 8

Explanation: The filing indicates a strong positive turnaround in the company's financial position, moving from a capital deficiency to significant positive equity and regaining Nasdaq compliance. This is a critical step for continued operations and investor confidence, despite the prior financial challenges and listing transfer.

Positives

• Achieved compliance with Nasdaq's $2.5 million shareholders' equity requirement, with current equity at approximately $9.41 million.
• Successfully completed multiple capital-raising transactions, including a public offering and warrant exercises, generating significant gross proceeds.
• Received a favorable decision from a Nasdaq hearings panel on July 7, 2025, allowing continued listing on the Nasdaq Capital Market.
• Reduced the outstanding amount of the Sponsor Convertible Note by $1.8 million to $1.6 million.

Negatives

• Previously reported a capital deficiency of $0.7 million as of July 31, 2025, and only $0.1 million shareholders' equity as of June 30, 2025, indicating prior financial distress.
• Listing was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, which may be perceived as a downgrade.
• The pro forma balance sheet is unaudited, and the company's independent registered public accounting firm has not conducted an audit or review, meaning adjustments may be required.

Risks

• Actual results could differ materially from forward-looking statements due to various risks and uncertainties.
• Caution must be exercised in relying on forward-looking statements, which speak only as of the date they were made.
• Other risks and uncertainties are detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent SEC filings.
• The unaudited pro forma balance sheet may be subject to adjustments by the company or its independent registered public accounting firm.

Future Outlook

The Company believes it has achieved compliance with, and expects to comply on a long-term basis with, the Nasdaq Equity Requirement. It awaits Nasdaq's confirmation of this compliance.

Management Comments

• Ilan Hadar, Chief Executive Officer, signed the report on behalf of Silexion Therapeutics Corp.

Industry Context

NA

Corporate Governance

Related Party Transactions

• Issuance of 450,000 ordinary shares to Moringa Sponsor, LP (the 'Sponsor') upon conversion of $1.8 million of the Sponsor Convertible Note.
• The Sponsor Convertible Note itself is a related party transaction.

Stakeholder Impact

• Shareholders: Positive impact due to regained Nasdaq compliance, reducing delisting risk and potentially improving investor confidence and liquidity. However, there was dilution from new share issuance and warrant exercises.
• Creditors: The partial conversion of the Sponsor Convertible Note reduces the company's debt obligations to a related party.
• Nasdaq: The company has met the conditions set by Nasdaq for continued listing.

Next Steps

• Awaits Nasdaq's confirmation of compliance with the Equity Requirement.
• Expects to comply on a long-term basis with the Nasdaq Equity Requirement.

Key Dates

Recommendation

While the company has successfully addressed its immediate Nasdaq listing compliance issues and significantly improved its shareholders' equity through recent capital raises, the prior capital deficiency and transfer to the Nasdaq Capital Market suggest underlying operational challenges. The recent capital raises involved significant dilution and warrant issuances. A 'hold' recommendation is appropriate as the company has stabilized its listing status, but further analysis of its core business performance and long-term financial sustainability is needed before a more aggressive stance can be taken. The unaudited nature of the pro forma balance sheet also warrants caution.

Keywords

Silexion Therapeutics, SLXN, Nasdaq Compliance, Shareholders Equity, Capital Raise, Public Offering, Warrant Exercise, SEC Filing, 8-K, Promissory Note Conversion